Funding will support the commercialization of AWAK Technologies’ disruptive platform, targeting the US$85 billion end-stage renal disease market Accuron MedTech, a division of Accuron Technologies Limited, today announced that it is leading an investment totalling US$11.2 million into AWAK Technologies, a Singapore medtech start-up developing solutions that address end-stage renal disease (ESRD). This funding will […]
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
